Coya Therapeutics, Inc. (COYA)

8.67 -0.38 (-4.20%) At close: 04:00PM EDT

Coya Therapeutics, Inc.

5850 San Felipe Street
Suite 500
Houston, TX 77057
United States
800 587 8170
https://www.coyatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Howard Berman Ph.D.	Chairman & CEO	833.75k	N/A	1974
Dr. Fred Grossman D.O., FAPA	President & Chief Medical Officer	610.63k	N/A	1962
Mr. David S. Snyder	CFO & COO	610.94k	N/A	1960
Dr. Gregory MacMichael Ph.D.	Chief Technical Officer	N/A	N/A	1956
Dr. Michelle Frazier Ph.D.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Mr. Aaron Thome Ph.D.	Head of Neuroinflammation Platform	N/A	N/A	N/A
Dr. Arun Swaminathan Ph.D.	Chief Business Development Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Corporate Governance

Coya Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.